Workflow
创新药ETF领涨，机构看好创新药行业业绩增长丨ETF基金日报
2 1 Shi Ji Jing Ji Bao Dao·2025-11-13 02:31

Market Overview - The Shanghai Composite Index fell by 0.07% to close at 4000.14 points, with a daily high of 4020.38 points [1] - The Shenzhen Component Index decreased by 0.36% to 13240.62 points, reaching a high of 13312.53 points [1] - The ChiNext Index dropped by 0.39% to 3122.03 points, with a peak of 3137.58 points [1] ETF Market Performance - The median return of stock ETFs was -0.21% [2] - The highest performing ETFs included: - Huatai-PB SSE Sci-Tech Innovation Board Innovative Drug ETF with a return of 1.99% [4] - Fuguo CSI Hong Kong-Shenzhen Innovative Drug Industry ETF at 1.89% [4] - Guotai CSI Hong Kong-Shenzhen Innovative Drug Industry ETF at 1.85% [4] - The worst performing ETFs included: - Penghua SSE Sci-Tech Innovation Board New Energy ETF with a return of -4.68% [5] - Hua'an CSI Photovoltaic Industry ETF at -4.42% [5] - Fuguo SSE Sci-Tech Innovation Board New Energy ETF at -4.32% [5] ETF Fund Flow - The top three ETFs by fund inflow were: - Huaxia SSE Sci-Tech Innovation Board 50 Component ETF with an inflow of 1.286 billion yuan [6] - Huabao CSI All-Index Securities Company ETF with 582 million yuan [6] - Guotai CSI All-Index Securities Company ETF with 577 million yuan [6] - The top three ETFs by fund outflow were: - Guotai CSI Coal ETF with an outflow of 337 million yuan [7] - Hua'an ChiNext 50 ETF at 294 million yuan [7] - E Fund CSI A500 ETF at 287 million yuan [7] ETF Margin Trading Overview - The highest margin buy amounts were: - Huaxia SSE Sci-Tech Innovation Board 50 Component ETF with 639 million yuan [8] - E Fund ChiNext ETF at 522 million yuan [8] - Guotai CSI All-Index Securities Company ETF with 421 million yuan [8] - The highest margin sell amounts were: - Huatai-PB SSE 300 ETF with 49.49 million yuan [9] - Huaxia SSE 50 ETF at 24.32 million yuan [9] - Fuguo CSI A500 ETF at 14.19 million yuan [9] Industry Insights - Everbright Securities noted that the performance growth trend in the innovative drug industry is expected to continue, driven by strong sales and business development transactions [10] - Guoxin Securities highlighted that the innovative drug sector has shown high revenue growth and profitability recovery, indicating a long-term positive development trend [10]